Text Size

A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm

This study has been completed.
Sponsor:
Collaborator:
BCN Peptides
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( Mark Hallet, M.D., National Institute of Neurogical Disorders and Stroke )
ClinicalTrials.gov Identifier:
NCT00942851
First received: July 18, 2009
Last updated: August 3, 2012
Last verified: August 2012
History of Changes
Results First Received: May 29, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Focal Dystonia
Interventions: Drug: Acetyl-Hexapeptide Topical Treatment
Drug: placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Active Topical intervention agent containing AH8 0.005% Twice daily application to the eyelids in standardized fashion.
Placebo

Topical intervention agent WITHOUT AH-8. Identically appearing cream without the active ingredient.

Twice daily application to the eyelids in standardized fashion.

Participant Flow:   Overall Study
    Active     Placebo  
STARTED     12     12  
COMPLETED     12     11  
NOT COMPLETED     0     1  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Active AH-8 containing topical intervention
Placebo topical intervention WITHOUT AH-8
Total Total of all reporting groups

Baseline Measures
    Active     Placebo     Total  
Number of Participants  
[units: participants]
 		  12     12     24  
Age  
[units: participants]
 		     
<=18 years     0     0     0  
Between 18 and 65 years     10     11     21  
>=65 years     2     1     3  
Age  
[units: years]
Mean ± Standard Deviation 		  57.59  ± 8.46     55.87  ± 8.25     56.73  ± 8.22  
Gender  
[units: participants]
 		     
Female     12     2     14  
Male     0     10     10  
Region of Enrollment  
[units: participants]
 		     
United States     12     12     24  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Time Until Jankovic Blepharospasm Rating Scale (JBRS) Reverts Back to Baseline   [ Time Frame: 3-7 months ]
  Show Outcome Measure 1

2.  Secondary:   Change in the JBRS at 3 Months   [ Time Frame: baseline to 3 months ]
  Show Outcome Measure 2

3.  Secondary:   % Blepharospasm Disability Scale (BDS) Change at 3 Months   [ Time Frame: baseline to 3 months ]
  Show Outcome Measure 3


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Codrin Lungu, MD
Organization: Office of the Clinical Director, NINDS, NIH
phone: 301-496-5295
e-mail: lunguci@ninds.nih.gov


Publications:


Responsible Party: National Institutes of Health Clinical Center (CC) ( Mark Hallet, M.D., National Institute of Neurogical Disorders and Stroke )
ClinicalTrials.gov Identifier: NCT00942851     History of Changes
Other Study ID Numbers: 090193, 09-N-0193
Study First Received: July 18, 2009
Results First Received: May 29, 2012
Last Updated: August 3, 2012
Health Authority: United States: Food and Drug Administration